Results 161 to 170 of about 13,786 (251)

Navigating Oral Food Challenges in Clinical Trials to Keep the Science Moving Forward

open access: yesAllergy, EarlyView.
ABSTRACT The oral food challenge (OFC) has long been the reference standard for food allergy diagnosis, as well as to confirm natural development of oral tolerance. The utilization of OFCs has significantly broadened from its role in defining disease to defining participant eligibility, individual allergen reactivity thresholds and treatment outcomes ...
Edwin H. Kim   +10 more
wiley   +1 more source

Mapping Allergen B‐ and T‐Cell Epitopes: Technological Advances and Their Role in Precision Allergy Therapy

open access: yesAllergy, EarlyView.
ABSTRACT Allergic diseases arise from aberrant immune recognition of otherwise harmless environmental proteins and are driven by epitope‐specific interactions between allergens and the adaptive immune system. Although component‐resolved diagnostics have improved molecular characterisation of sensitization, they remain limited to whole‐allergen ...
Mark Møiniche   +11 more
wiley   +1 more source

Student profiles of change in formative assessment behaviour: Replication and evaluation for grade prediction

open access: yesBritish Journal of Educational Technology, EarlyView.
Abstract As students learn and practice new skills in university courses, their behaviour can change in response to competing demands and increasing content complexity. However, most metrics used to evaluate study behaviour focus on the number or sequence of activities rather than on the change of behaviour.
Oleksandra Poquet   +2 more
wiley   +1 more source

Reporting cell planning-based cellular mobility management using a Binary Artificial Bat algorithm. [PDF]

open access: yesHeliyon, 2019
Swayamsiddha S   +4 more
europepmc   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

open access: yesBritish Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo   +3 more
wiley   +1 more source

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

open access: yesBritish Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy